News Releases

RNS Number : 3045E MaxCyte, Inc. 29 June 2023     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   ROCKVILLE, MD , June 29, 2023 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to
Jun 29, 2023
RNS Number : 7871D MaxCyte, Inc. 23 June 2023     MaxCyte, Inc. (" MaxCyte " or the "Company")   Grant of Options   ROCKVILLE, MD , June 23, 2023 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the
Jun 23, 2023
RNS Number : 7204D MaxCyte, Inc. 23 June 2023     Result of AGM   Rockville, MD , June 23, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as
Jun 23, 2023
RNS Number : 6635D MaxCyte, Inc. 23 June 2023     Result of AGM   Rockville, MD , June 23 , 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as
Jun 23, 2023
RNS Number : 4553D MaxCyte, Inc. 21 June 2023   Publication of Annual Report   ROCKVILLE, MD , June 21, 2023   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and
Jun 21, 2023
RNS Number : 0358D MaxCyte, Inc. 16 June 2023     MaxCyte, Inc. (" MaxCyte " or the "Company")   Exercise of options and PDMR dealing   Gaithersburg, Maryland - 16 June 2023 :   MaxCyte Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
Jun 16, 2023
RNS Number : 3691B MaxCyte, Inc. 02 June 2023   MaxCyte to Participate in Upcoming Investor Conferences Rockville, MD , June 2, 2023 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance innovative
Jun 02, 2023
ROCKVILLE, Md., June 01, 2023 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development
Jun 01, 2023
RNS Number : 2294B MaxCyte, Inc. 01 June 2023   MaxCyte, Inc.   (" MaxCyte " or the "Company")   Total Voting Rights   Gaithersburg, Maryland - 1 June 2023:         MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
Jun 01, 2023
RNS Number : 0855Z MaxCyte, Inc. 11 May 2023       MaxCyte announces filing of Form 10-Q for the quarterly period ended March 31, 2023   ROCKVILLE, MD , May 11, 2023   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies
May 11, 2023